UK
Sara Holloway
I have over ten years of experience in Microsoft SQL Server database administration and development, including data modeling, design and ETL processes. I work across our health analytics practice and I help to build the required infrastructure that collects, manages, and converts raw data into usable information for analysis, in line with our clients’ key objectives.
I particularly enjoy exploring insightful and interesting patterns from the raw data and turning it into useful, actionable information across a range of projects.
Every piece of communication we have received from the LCP team has been phenomenally clear. They provide firm recommendations and as a client I couldn't have asked for more.
LCP client
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Is trade strategy part of your C-suite dialogue, and is it at a market or global level?
Natalie Rush explains why trade strategy must be a C-suite priority for pharma leaders, showing how aligning commercial, market access, and operational pathways can accelerate speed to market, control costs, and expand patient access globally.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
